Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 4.4% – Here’s What Happened

Tiziana Life Sciences Ltd (NASDAQ:TLSA)’s share price fell 4.4% on Wednesday . The stock traded as low as $1.29 and last traded at $1.31. 142,637 shares were traded during trading, an increase of 48% from the average session volume of 96,068 shares. The stock had previously closed at $1.37.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tiziana Life Sciences in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Tiziana Life Sciences presently has a consensus rating of “Sell”.

Tiziana Life Sciences Trading Down 3.2%

The company’s fifty day simple moving average is $1.45 and its 200-day simple moving average is $1.67.

Hedge Funds Weigh In On Tiziana Life Sciences

Institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new stake in Tiziana Life Sciences during the first quarter worth $25,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Tiziana Life Sciences in the 4th quarter valued at $25,000. Bison Wealth LLC bought a new position in shares of Tiziana Life Sciences in the 4th quarter worth $30,000. HRT Financial LP purchased a new stake in shares of Tiziana Life Sciences during the 4th quarter worth $36,000. Finally, Marshall Wace LLP purchased a new stake in shares of Tiziana Life Sciences during the 2nd quarter worth $39,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.